FDA Approves IDE Trial of Nerve Stimulation Therapy for Epilepsy

NeuroSigma Announces FDA Approval to Commence Phase III Trial (via PR Newswire)

External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Epilepsy LOS ANGELES, July 29, 2013 /PRNewswire/ — NeuroSigma, Inc., today announced conditional approval by the U.S. Food and Drug Administration (FDA) of its Investigational Device…